Patients with resectable pancreatic body or tail cancer who have splenic vein (SPV) involvement, particularly radiological SPV encasement, experience significantly worse overall survival (OS) and recurrence-free survival (RFS). Independent poor prognostic factors include higher pre-operative carcinoembryonic antigen levels, larger tumor size, pathological SPV invasion, and non-completion of adjuvant therapy. Multidetector-row computed tomography shows relatively high […]

Patient-controlled epidural analgesia (PCEA) did not significantly improve postoperative pain during ambulation compared to intravenous patient-controlled analgesia (IV PCA) following open hepatectomy. There was a small difference in pain scores on postoperative day 2, but it did not meet the pre-specified definition of clinical significance. PCEA was safe with a low incidence of epidural failure […]

Researchers developed and validated a new clinically relevant endpoint, Pancreatic Surgery Composite Endpoint (PACE), for pancreatic surgery. PACE incorporates postoperative pancreatic fistula, post-pancreatectomy hemorrhage, reoperation, and reinterventions. It demonstrated high predictive value for prolonged length of hospital stay (LOS) and mortality in both the development and validation cohorts. PACE allowed for significant reduction in sample […]

Researchers identified benchmark values for hepatectomy in intrahepatic cholangiocarcinoma (ICC) across international institutions. Out of 1,193 patients, 600 (50.3%) were included in the benchmark group. The benchmark values encompassed criteria such as lymph node retrieval, blood loss, transfusion rate, operative time, achievement rates for postoperative outcomes, resection margin, complications, mortality, and hospital stay. Establishing these […]

The study compared the outcomes of patients with middle-third cholangiocarcinoma who underwent modified pancreaticoduodenectomy (MPD) or hepatopancreaticoduodenectomy (HPD). The MPD group exhibited advantages such as shorter operation time, less blood loss, and fewer complications compared to the HPD group. Overall survival rates did not significantly differ between the groups. The study identified positive surgical margins […]

A proposed model called the aMAP score was evaluated for its ability to predict long-term outcomes in patients undergoing resection for hepatocellular carcinoma (HCC). The results showed that a high aMAP score was associated with poorer 5-year overall survival (OS) rates compared to a low aMAP score. The aMAP score was also found to be […]

Researchers conducted a study to investigate resection to exploration ratios (RER) and outcomes in patients with pancreatic ductal adenocarcinoma (PDAC). The overall RER was found to be 89.7%, with higher ratios observed in upfront explorations compared to post-neoadjuvant explorations. The primary reasons for uncompleted resection were occult metastases in presumed resectable/borderline resectable disease and local […]

A study found that combining an oncolytic virus with CD19-Chimeric Antigen Receptor-T (CAR-T) cells was effective in treating pancreatic cancer. The engineered virus successfully infected and expressed CD19 on tumor cells, leading to an increased immune response and cell killing when co-cultured with CD19-CAR-T cells. In combination therapy, the virus and CAR-T cells significantly reduced […]

Body fat mass loss was analyzed in patients undergoing radical resection for pancreatic ductal adenocarcinoma (PDAC) using bioelectrical impedance analysis. The study found that a body fat mass loss of ≥14% one month after surgery was associated with a poor prognosis. Lymph node metastasis and non-adjuvant chemotherapy were also identified as independent poor prognostic factors. […]